Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

A Houston-based compounding pharmacy has fired back against a lawsuit filed by the pharmaceutical giant that makes Mounjaro ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Shares of Eli Lilly & Co. LLY rallied 4.33% to $807.19 Tuesday, on what proved to be an all-around positive trading session ...